unknown
Stage
1
Investors
About
Immunethep develops immunotherapies to enhance the host immune response against bacterial infections, targeting antimicrobial resistance. Its pipeline includes multivalent preventive and therapeutic products such as vaccines and monoclonal antibodies for infectious diseases.
Explore Immunethep's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.